Aethlon Medical AEMD Stock News

Aethlon Medical, Inc. (NASDAQ: AEMD) is running for the top in the market this morning, gaining well over 100%. The gains come after the company announced that the FDA has approved a supplement that will allow the company to test a device in COVID-19 patients. Here’s the scoop:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

AEMD Stock Rockets On FDA News

In the press release, Aethlon Medical said that the FDA has approved a supplement to its existing Investigational Device Exemption surrounding its Hemopurifier. The approved supplemntal IDE allows for the testing of the hemopurifier in patients with SARS-CoV-2/COVID-19 in a new feasibility study.

In the release, the company reminded inestors that a feasibility study is the equivalent of a Phase 1 clinical trial. The study will enroll up to 40 patients at 20 centers in the United States. All subjects enrolled will have an established laboratory diagnosis of COVID-19.

Moreover, AEMD said that all patients in the studdy will have been admitted to the ICE and have acute lung injury and/or severe or life threatening disease among other criteria.

Importantly, the Hemopurifier has been tested in patients with hepatitis C virus infection and one patient with Ebola infection. Moreover, a laboratory version of the Hemopurifier has been shown to clear multiple other viruses in vitro, including a model version of MERS, a sister virus to the virus that causes COVID-19.

In a statement, Timothy C. Rodell, M.D., CEO at AEMD, had the following to offer:

We believe that the Hemopurifier may have the potential to help severely affected patients with COVID-19. We believe that clearing circulating virus in these patients, in combination with other supportive measures, could improve outcomes in this deadly disease.

This Is Huge News

The news released by Aethlon Medical this morning was overwhelmingly positive. As the United States works to reopen its economy, we’re starting to see a resurgence of COVID-19 infections.

However, we’re stuck between a rock and a hard place. Reclosing the economy would mean economic devastation that simply isn’t worth the risk. Keeping the economy open subjects millions to COVID-19 infection.

So, what we really need is viable vaccines and treatments. With the FDA approving the company’s request to study this product as a potential treatment option, it joins the race among very few competitors that are this far along in the development of a treatment. All in all, that makes AEMD a stock that’s hard to ignore.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.